Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report

BACKGROUND: The onset of myasthenia (MG) gravis with anti-muscle-specific tyrosine kinase (MuSK) antibodies most commonly peaks in the fourth decade of life, and MG with MuSK antibodies (MuSK-MG) rarely coexists with a malignant tumor. To date, MuSK-MG has not been reported in multiple myeloma (MM)....

Descripción completa

Detalles Bibliográficos
Autores principales: Sakano, Shoko, Matsuyama, Hirofumi, Ishikawa, Hidehiro, Shindo, Akihiro, Ii, Yuichiro, Matsuura, Keita, Mizutani, Minoru, Kawada, Norikazu, Tomimoto, Hidekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291755/
https://www.ncbi.nlm.nih.gov/pubmed/32532281
http://dx.doi.org/10.1186/s12883-020-01813-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291755/
https://www.ncbi.nlm.nih.gov/pubmed/32532281
http://dx.doi.org/10.1186/s12883-020-01813-1

Ejemplares similares